The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease

Acta Psychiatrica Scandinavica

Volumn 124, Issue 3, 2011, Pages 184-192

  Vanmierlo, T ^a,b   Popp, J ^c   Kolsch H ^c   Friedrichs, S ^a   Jessen, F ^c   Stoffel Wagner, B ^a   Bertsch, T ^d   Hartmann, T ^e   Maier, W ^c   von Bergmann, K ^a   Steinbusch, H ^b   Mulder, M ^f   Lutjohann D ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

^d Institute of Clinical Chemistry   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Brassicasterol; Cerebrospinal fluid; Cholesterol; Phytosterols; Sitosterol

Indexed keywords

ALBUMIN; AMYLOID BETA 42 PROTEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; BRASSICASTEROL; CAMPESTEROL; CREATININE; SITOSTEROL; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MINI MENTAL STATE EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; CHOLESTEROL; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; PHYTOSTEROLS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS; TAU PROTEINS;

EID: 80051664950     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01713.x     Document Type: Article

References (57)

1. Itoh N, Arai H, Urakami K et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-156.
2. De Leon MJ, Desanti S, Zinkowski R et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394-401.
3. Du AT, Schuff N, Kramer JH et al. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain 2007;130:1159-1166.
4. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006;314:777-781.
5. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008;4:38-48.
6. Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
7. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119:252-265.
8. Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand 2003;107:390-393.
9. Luck T, Riedel-Heller SG, Luppa M et al. Risk factors for incident mild cognitive impairment - results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Acta Psychiatr Scand 2010;121:260-272.
10. Mulder M. Sterols in the central nervous system. Curr Opin Clin Nutr Metab Care 2009;12:152-158.
11. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993;34:1637-1659.
12. Segal MB. The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell Mol Neurobiol 2000;20:183-196.
13. Pollak OJ, Kritchevsky D. Sitosterol. Monogr Atheroscler 1981;10:1-219.
14. Salen G, Ahrens EH Jr, Grundy SM. Metabolism of beta-sitosterol in man. J Clin Invest 1970;49:952-967.
15. Fricke CB, Schroder M, Poulsen M et al. Increased plant sterol and stanol levels in brain of Watanabe rabbits fed rapeseed oil derived plant sterol or stanol esters. Br J Nutr 2007;98:890-899.
16. Jansen PJ, Lutjohann D, Abildayeva K et al. Dietary plant sterols accumulate in the brain. Biochim Biophys Acta 2006;1761:445-453.
17. Fassbender K, Lutjohann D, Dik MG et al. Moderately elevated plant sterol levels are associated with reduced cardiovascular risk - the LASA study. Atherosclerosis 2008;196:283-288.
18. Fratiglioni L, Launer LJ, Andersen K et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S10-S15.
19. Hebert LE, Scherr PA, Beckett LA et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-1359.
20. Lobo A, Launer LJ, Fratiglioni L et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4-S9.
21. Andreasen N, Gottfries J, Vanmechelen E et al. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71:557-558.
22. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007;68:1809-1814.
23. Wada H. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Intern Med 1998;37:509-513.
24. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric PressAmerican Psychiatric Press, 1994.
26. Folstein MF, Folstein SE, Mchugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
27. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
28. Algotsson A, Winblad B. The integrity of the blood-brain barrier in Alzheimer's disease. Acta Neurol Scand 2007;115:403-408.
29. Horani MH, Mooradian AD. Effect of diabetes on the blood brain barrier. Curr Pharm Des 2003;9:833-840.
30. Sunitha Y, Udaykumar P, Raghunath M. Changes in blood-brain barrier nutrient transport in the offspring of iodine-deficient rats and their preventability. Neurochem Res 1997;22:785-790.
31. Nixon PF, Jordan L, Zimitat C, Rose SE, Zelaya F. Choroid plexus dysfunction: the initial event in the pathogenesis of Wernicke's encephalopathy and ethanol intoxication. Alcohol Clin Exp Res 2008;32:1513-1523.
32. Ferrari CC, Depino AM, Prada F et al. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am J Pathol 2004;165:1827-1837.
33. Teunissen CE, De Vente J, Von Bergmann K et al. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol Aging 2003;24:147-155.
34. Kolsch H, Heun R, Jessen F et al. Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 2010;1801:945-950.
35. Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? Neurosci Lett 2006;397:83-87.
36. Blennow K, Fredman P, Wallin A et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88years of age. Eur Neurol 1993;33:129-133.
37. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-390.
38. Spector R, Johanson CE. The mammalian choroid plexus. Sci Am 1989;261:68-74.
39. Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T. 24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J Neurochem 2007;100:968-978.
40. Hubacek JA, Berge KE, Cohen JC, Hobbs HH. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Hum Mutat 2001;18:359-360.
41. Serot JM, Bene MC, Foliguet B, Faure GC. Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathol 2000;99:105-108.
42. Wen GY, Wisniewski HM, Kascsak RJ. Biondi ring tangles in the choroid plexus of Alzheimer's disease and normal aging brains: a quantitative study. Brain Res 1999;832:40-46.
43. Hagnelius NO, Wahlund LO, Nilsson TK. CSF/serum folate gradient: physiology and determinants with special reference to dementia. Dement Geriatr Cogn Disord 2008;25:516-523.
44. Ikeda T, Furukawa Y, Mashimoto S, Takahashi K, Yamada M. Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer's disease. Acta Psychiatr Scand 1990;82:327-329.
45. Jimenez-Jimenez FJ, De Bustos F, Molina JA et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J Neural Transm 1997;104:703-710.
46. Riisoen H. Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol Scand 1988;78:455-459.
47. Serot JM, Christmann D, Dubost T, Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997;63:506-508.
48. Jellinger K, Rett A. Agyria-pachygyria (lissencephaly syndrome). Neuropadiatrie 1976;7:66-91.
49. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995;333:1308-1312.
50. Thompson GR, Grundy SM. History and development of plant sterol and stanol esters for cholesterol-lowering purposes. Am J Cardiol 2005;96:3D-9D.
51. Guardia-Laguarta C, Coma M, Pera M et al. Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. J Neurochem 2009;110:220-230.
52. Hayashi H, Igbavboa U, Hamanaka H et al. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 2002;13:383-386.
53. Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 2010;1801:860-867.
54. Wahrle S, Das P, Nyborg AC et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 2002;9:11-23.
55. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-393.
56. Mulder C, Verwey NA, Van Der Flier WM et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248-253.
57. De Meyer G, Shapiro F, Vanderstichele H et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010;67:949-956.